Refusing to slow down since the start of the new year, shares of Tempus AI (NASDAQ: TEM) have skyrocketed nearly 99% since ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free ...

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal ...

All thanks to three key catalysts. Up about 12%, Tempus AI (NASDAQ: TEM) is rocketing thanks to three key catalysts. One, Tempus AI just acquired Ambry Genetics. Two, Nancy Pelosi and Cathie Wood ...

This month, tempus’s generative AI (genAI) assistant, Tempus One, launched a range of new capabilities for running queries on millions of unstructured documents for research and clinical care.

Tempus recently gained in-network provider status with Blue Cross Blue Shield across multiple states, allowing for the firm's tests to be covered by insurance. One of Tempus’ business objectives ...

making Tempus AI a one-stop shop for AI-driven diagnostics. As you'd imagine, there are many different competitors in the space that are also eager to take market share, for example, Guardant ...

Looking at options history for Tempus AI TEM we detected 21 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish ...

On January 14, the company unveiled a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, the company’s generative AI-enabled ...

Tempus AI was one of them. Pelosi purchased 50 call options with a strike price of $20 that also expire on Jan. 16, 2026. The value of the trade was between $50,000 and $100,000. The other stock ...

One, Tempus AI just acquired Ambry Genetics. Two, Nancy Pelosi and Cathie Wood are bullish on Tempus AI. Three, TD Cowen just upgraded the TEM stock to a buy with a $74 price target.